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Abstract
Background: The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late
diagnosis. We determined the performances of a -1-acid glycoprotein (AAG) and des-g-carboxy prothrombin (DCP)
for the diagnosis of HCC, especially for a-fetoprotein (AFP)-low HCC.
Methods: Of the 220 patients included in this retrospective study, 124 had HCC, and 61 (49%) of these were AFP-
low HCC (AFP ≤ 20 ng/mL). The remaining 96 patients, including 49 with chronic hepatitis B or C and 47 with
cirrhosis, were considered as control. Plasma AAG was analyzed using high performance liquid chromatography
(HPLC) and confirmed using Western blot technique.
Results: When all patients with HCC were evaluated, the area under receiver operating characteristic (ROC) curves
for AAG (0.94, 95% CI: 0.91-0.97) and DCP (0.92, 95% CI: 0.88-0.95) were similar (P = 0.40). AAG had better area
under ROC curve (0.96, 95% CI: 0.94-0.99) than DCP (0.87, 95% CI: 0.81-0.93) for AFP-low HCC (P < 0.05). At the
specificity 95%, the sensitivity of AAG was higher in AFP-low HCC than in AFP-high HCC (82% and 62%,
respectively). In contrast, higher sensitivity was obtained from DCP in discriminating HCC patients with low AFP
than that in high AFP (57% and 90%, respectively).
Conclusion: Our cross-sectional study showed that AAG was better performance in diagnosing HCC patients with
low AFP, while DCP did better in those with high AFP.
Background
Hepatocellular carcinoma (HCC) is one of the most
common malignancies in the world [1]. Until recently,
AFP has been the most widely used plasma marker for
diagnosis, surveillance, and as a prognostic indicator of
HCC patients’ survival [2]. Several studies indicated that
high plasma levels of AFP are related to poor prognosis,
as well as histologic grade of malignancy [3]. Those with
high plasma AFP level at the time of HCC diagnosis
have more unfavourable outcomes compared to patients
with low AFP level [4]. However, it has been recognized
that AFP has a low sensitivity in detection of HCC, and
that AFP level often increases in the absence of HCC
[5].
To date, several tumor markers have been proposed as
complement or substitute for AFP in HCC diagnosis.
Recently, Lens culinaris agglutinin-reactive fraction of
AFP (AFP-L3) [6] and DCP [7] have been approved by
the Food and Drug Administration as plasma markers
for HCC. AFP-L3 can be detected in the plasma of
patients with small tumors [8,9]. However, for the diag-
nosis of early stage of HCC, AFP-L3 [10] and DCP
[10,11] are less sensitive than AFP for the diagnosis of
early and very early stage HCC. DCP has not been used
in Indonesia and it could be a potential biomarker for
diagnosis of HCC. Therefore a cross-sectional study is
required to determine the role of DCP in the diagnosis
of HCC in the Indonesian population. Another potential
biomarker for HCC is AAG. AAG is an acute phase
protein, synthesized predominantly in the liver. Cyto-
kines can cause plasma AAG level to increase as part of
an inflammatory response [12]. The plasma level of
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diagnosing cirrhosis and HCC [13]. Recently we have
shown that combination of AAG and AFP improves the
accuracy of HCC diagnosis [14].
Given the rising incidence of HCC in Indonesia and
lack of data on the clinical utility of these two tumor
markers (AAG and DCP) for detecting the presence of
HCC, we selected 220 chronic liver patients, with and
without HCC. This study is a further step in order to
assess the feasibility of AAG to diagnose AFP-low HCC.
This study has limitations, and not designed to assess
the treatment and follow-up of the screen-detected
patients. Our specific aims were to: (i) define the level
of each tumor marker with the best sensitivity, specifi-
city, accuracy, positive predictive value (PPV) and nega-
tive predictive value (NPV) for diagnosis of HCC; and
(ii) to evaluate the clinical utilities of AAG and DCP in
HCC patients with low AFP (≤ 20 ng/mL) and high
AFP (> 20 ng/mL), especially in attempt to find the best
biomarker for diagnosing HCC patients with low AFP.
Methods
Patients
A total of 220 plasma samples were collected between
January 2006 and January 2009 from patients in four
participating hospitals, Cipto Mangunkusumo Hospital,
Gatot Subroto Army Hospital, Ali Sulaiman Liver Clinic
Center (Jakarta, West Indonesia) and Hepatitis Labora-
tory Mataram (West Nusa Tenggara, East Indonesia).
Demographic and clinical information of each patient
including age, gender, and cause of disease were
obtained from chart review. All patients gave informed
consents to participate in the study, and the Institutional
Review Board of each participating institution approved
the protocol.
The patients were divided into three groups: (i) con-
trol (non-malignant disease), either chronic hepatitis
patients with HBV/HCV infection (n = 49) or cirrhotic
patients (n = 47); (ii) AFP-low HCC (n = 61); and (iii)
AFP-high HCC (n = 63). Etiology of underlying liver
disease was attributed to HBV based on detection of
HBsAg in plasma via a commercial assay and HCV
based on detection of hepatitis C antibody/hepatitis C
virus RNA in plasma. The presence of cirrhosis was
defined by histological measurement or non-histological
by evidence of portal hypertension in the presence of
chronic liver disease. Diagnosis of HCC relied on the
presence of a malignant liver nodule, as established by
imaging techniques. Fine needle aspiration biopsy proce-
dure reconfirmed the diagnosis of HCC for sample in
which the AFP concentration was low. Subjects with
HIV co-infection or autoimmune hepatitis were
excluded in this study. None of the subjects was taking
vitamin K at time of the study.
Biomarkers measurements
Blood samples were collected in pyrogen-free tube (BD
Vacutainer, Plymouth, UK) with ethylene diamine tetra-
acetic acid as an anticoagulant. A 10 mL blood sample
was drawn from each subject, and plasma was stored at
-80°C until AFP, AAG, and DCP testing.
The quantitative measurement of plasma AFP or DCP
was performed using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit from Amgenix
International Inc. (San Jose, CA, USA) or from Diagnos-
tica Stago (Asnières-sur-Seine, France), respectively,
according to the manufacturers’ instructions. The mini-
mum detectable concentration for both AFP and DCP
were 2.0 ng/mL.
Measurement of plasma AAG concentration was per-
formed according to our previous report [14]. Briefly,
the plasma AAG level was detected via the Agilent 1200
HPLC system. A 200 μL of crude plasma was diluted
with 600 μL of Buffer A (Agilent, Santa Clara, CA). An
amount of 20 μL of the diluted plasma was depleted on
a Multiple Affinity Removal Column (Agilent; 4.6 mm ×
50 mm) according to the manufacturer’si n s t r u c t i o n s .
The total volume of depleted plasma collected at reten-
tion time between 2 and 6 min was approximately 1
mL. The depleted plasma was fractionated by column
mRP-C18 (Agilent; 4.6 mm × 50 mm), operated at flow
rate 0.75 mL/min and mobile phase comprised of two
solvents: A: water/0.1% trifluoroacetic acid (TFA) and B:
Acetonitrile/0.08% TFA. The AAG fraction was detected
between retention times at 14.5-16 minute. Quantifica-
tion of plasma AAG concentration was performed using
ovalbumine as an external standard and for calibration
sample. Measurement of the standard was calculated
based on peak area integration according to the Agilent
Chemstation protocol.
Western blot
The result from HPLC analysis was validated using Wes-
tern blot. We selected 8 samples randomly from each
group, chronic hepatitis, cirrhosis, AFP-low HCC, and
AFP-high HCC, respectively. An amount of 25 μL plasma
was depleted using Multiple Affinity Removal Column
(Agilent). The low-abundant protein fractions were col-
lected and concentrated to 100 μL. Then, 10 μLo ft h e
concentrated fractions were mixed with Laemmli sample
buffer and applied to 12% SDS-PAGE gels. Proteins in
the gels were transferred to 0.45 μm nitrocellulose mem-
branes. The membranes were blocked using 5% skim
milk in TBS-T (20 mM Tris-HCl pH 7.5, 500 mM
sodium chloride, 0.05% Tween 20) at room temperature
for one hour. The blots were washed twice using TBS-
TT (TBS-T containing 0.2% Triton) and once using TBS
(10 mM Tris-HCl pH 7.5, 150 mM sodium chloride).
Incubation with primary antibody was done overnight at
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( S i g m a ,I n c . ,S t .L o u i s e ,M O ,U S A )i nb l o c k i n gb u f f e r .
The membranes were washed twice with TBS-TT, once
with TBS, incubated for two hours with anti-mouse IgG
HRP-linked antibody (GE Healthcare, Buckinghamshire,
U K )a ta1 : 5 0 0 0d i l u t i o ni nT B S - T ,a n dw a s h e dt h r e e
times with TBS-TT. The blots were developed using dia-
minobenzidine (DAB) substrate (40 mg/mL DAB, 80 mg/
mL nickel chloride, and 30% H2O2 in 0.1 M Tris-HCl pH
7.5). The stained membranes were then scanned and
quantified using ImageJ softwa r e( N a t i o n a lI n s t i t u t eo f
Health, Bathesda, MD, USA) by measuring the relative
intensity from each band.
Statistical analysis
Comparison of clinical characteristics, plasma biomarker
levels, and Western blot relative intensities among the
groups were analyzed using parametric or non-para-
metric analyses based on data distribution. For normal
distributed data, differences between groups were ana-
lyzed using Student’s t-test. For non-parametric distribu-
ted data and binary variables, Mann Whitney was
performed to compare groups. The descriptive statistics
for the markers were compared by scatter plots using
the GraphPad Prism 5.02 (GraphPad Inc., CA, USA). To
determine the optimal cut-off values for AFP, AAG, and
DCP in the diagnosis of HCC, Receiver Operating Char-
acteristic (ROC) curves were constructed using all the
possible cut-offs for each assay. The area under the
ROC curve (AUC) was calculated and compared. Statis-
tical analysis was performed using the SPSS 15.0 (SPSS
Inc., IL, USA).
Results
Patient characteristics
A total of 220 patients were included in this study, of
which 96 were control and 124 were HCC cases. Of the
cases, 61 were AFP-low and 63 were AFP-high. Both the
AFP-low and AFP-high HCC patients were older than
control (P = 0.01). All groups had more male than
female patients. The characteristics of these patients
were shown in Table 1. The majority of control and
cases had a viral etiology of their liver diseases, with
HBV in 57 patients out of 96 controls and 71 out of 124
HCC cases, of which 29 were AFP-low HCC. HCV was
the underlying etiology of liver disease in 32 patients
control and 30 HCC cases of which 12 were AFP-low
HCC. Other HCC patients had a non-viral etiology (non
B, non C) of their liver diseases, with 20 AFP-low and 3
AFP-high HCC patients.
Biomarker levels
HPLC chromatogram analysis showed that peak of AAG
at retention time 14.5-16 minute revealed high protein
expression in staging of HCC patients with low AFP
and high AFP concentration, but this peak was notably
smaller in control (Figure 1A). Furthermore, the result
from Western blot showed level of AAG in HCC
patients with low AFP and high AFP were significantly
elevated than those in controls (P <0 . 0 0 1 ) ,w h i c hw a s
consistent with the result of HPLC (Figure 1B).
The AFP, AAG, and DCP values were reported as
median because of the skewed data distribution. The
AFP level was lower in control than in HCC patients
(P < 0.0001), with median (range) 2.9 ng/mL (0.4-151.8
ng/mL) and 29.3 ng/mL (0.4-444550 ng/mL), respec-
tively. We observed plasma AFP values above 20 ng/mL
in 13 (13.5%) patients of control. Although AFP values
among some patients of control were higher than 20
ng/mL, histological investigations showed no HCC.
Plasma AAG values were significantly higher in HCC
than in control (P < 0.0001). The median (range) values
for control, AFP-low and AFP-high were 369.5 μg/mL
(108.2-883.9 μg/mL), 1501.2 μg/mL (395.6-4419.5 μg/
mL) and 950.4 μg/mL (387.2-2748.8 μg/mL), respec-
tively. Significant difference between control and HCC
was also observed in DCP values (P < 0.0001) with med-
ian (range) values were 1.5 ng/mL (0.5-12.3 ng/mL), 6.3
ng/mL (0.9-4273.8 ng/mL) and 356.4 ng/mL (0.4-14245
ng/mL), in control, AFP-low and AFP-high, respectively.
Values for AFP, AAG, and DCP were shown in Figure 2.
Area under the ROC curves
As shown in Figure 3, when all patients with HCC were
evaluated, the AUC for total AAG (0.94, 95% CI: 0.91-
0.97) was similar to that for DCP (0.92, 95% CI: 0.88-
0.95) (P = 0.40), but higher than AFP (0.75, 95% CI:
0.69-0.81) (P < 0.0001). When AFP-high HCC was com-
pared to control, DCP had higher AUC (0.96, 95% CI:
0.93-1.0) than AAG (0.91, 95% CI: 0.87-0.96; P = 0.08).
In contrast, when AFP-low HCC was compared to con-
trol, AAG had AUC (0.96, 95% CI: 0.94-0.99) better
than DCP (0.87, 95% CI: 0.81-0.93; P < 0.01) indicating
that AAG was more predictive of AFP-low HCC than of
AFP-high HCC. Clinical performances of AAG and DCP
were shown in Table 2.
Sensitivity, specificity, accuracy, PPV, and NPV of AAG
and DCP
Based on 95% specificity, cut-off for AAG was revised
from previous study [14] and increased to 800 μg/mL.
Using the cut-off, higher specificity was reached, with
sensitivity, accuracy, PPV and NPV were 71%, 82%, 95%,
and 72%, respectively. There were 11 (8.9%) AFP-low
and 24 (19.4%) AFP-high HCC patients who had AAG
values below the cut-off. In addition, there were 5
(5.2%) patients of control who had AAG values above
the cut-off.
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ng/mL. In clinical studies of patients with liver disease,
i n s t e a do fu s i n gc u t - o f fa t7 . 5n g / m L[ 1 5 ] ,ad e c i s i o n
cut-off of 4.5 ng/mL was found to be optimal, giving
better clinical performances. The sensitivity, accuracy,
P P V ,a n dN P Vw e r e7 4 % ,8 3 % ,9 5 % ,a n d7 4 % ,r e s p e c -
tively. Based on the cut-off value, we observed 32
(25.8%) HCC patients had DCP values below the cut-off,
while 5 (5.2%) patients of control had values above the
cut-off.
Table 1 Clinical characteristics of patients
Variable Control (n = 96) HCC (n = 124) P-value (vs. control)
Chronic Hepatitis
(n = 49)
Cirrhosis
(n = 47)
AFP ≤ 20 ng/mL
(n = 61)
AFP > 20 ng/mL
(n = 63)
AFP-Low HCC AFP-high HCC
Age 42.4 ± 14.9 53.8 ± 9.2 55.8 ± 14.6 53.5 ± 12.9 0.0008 0.0127
Gender (M:F) 25:24 31:16 41:20 51:12 0.2659 0.0030
Etiology (%) 0.0124 0.2458
HBV 69.4 48.9 47.5 66.7
HCV 30.6 36.2 19.7 28.6
Non HBV-non-HCV 0 14.9 32.8 4.8
AST (IU/mL) 32.5 (12-194) 42 (16-110) 91 (5-714) 138 (9-945) 0.0026 < 0.0001
ALT (IU/mL) 32.5 (6-868) 32 (15-63) 46 (8-363) 65 (6-347) < 0.0001 < 0.0001
Data presented as mean ± SD or median (range)
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, a-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase
Figure 1 HPLC chromatogram profile and western blot analysis. (A) HPLC chromatogram profile of chronic hepatitis, cirrhosis, AFP-low HCC,
and AFP-high HCC; (B) Western blot analysis of AAG in chronic hepatitis, cirrhosis, AFP-low HCC, and AFP- high HCC.
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DCP were better than those of AAG. However, when
ROC analysis was done in AFP-low HCC patients clini-
cal performances of AAG increased over DCP. Sensitiv-
ity, accuracy, PPV, and NPV of AAG (82%, 90%, 91%,
and 89%, respectively) were better than those of DCP
(57%, 80%, 88%, and 78%, respectively). In AFP-high
HCC patients, DCP was proven to be better than AAG.
The sensitivity, accuracy, PPV, and NPV of DCP were
90%, 93%, 92%, and 94%, respectively, while the corre-
sponding values for AAG were 62%, 82%, 89%, and 79%.
Discussion
According to the World Health Organization (WHO),
the incidence of HCC in Indonesia is projected to stea-
dily increase until 2030 due to increasing frequency of
cirrhosis in patients with chronic HBV infection [16].
Surveillance programs have been done based on abdom-
inal ultrasound examination and plasma AFP measure-
ment every six months. However, AFP was found to be
a poor complement for ultrasound, because of its low
sensitivity and specificity [17], therefore, a search for
new biomarkers for HCC is needed.
Several tumor markers have been proposed as comple-
ments or substitutes for AFP in HCC diagnosis. Plasma
concentration of AAG has been suggested as a potential
marker for cirrhosis and HCC [13,14]. A study by Kang
et al. found that AAG had similar sensitivity value in
differentiating HCC regardless of the tumor size [18].
While in our previous study, the diagnostic efficacy of
AAG among the HCC patients with AFP levels below
200 ng/mL was similar to the results from total HCC
patients [14]. This previous study clearly demonstrates
that the plasma AAG concentration was increased in
patients with HCC in comparison to patients with non-
HCC. In this study, when the ROC of AAG was com-
pared among HCC patients, the AAG level was signifi-
cantly higher in HCC patients with low AFP value but
lower in HCC patients with high AFP values. These
results were supported by another study that mentioned
the use of AAG to diagnose HCC patients whose AFP
values were below 500 ng/mL [18]. Since AFP level was
Figure 2 Scatter plots of plasma AFP, AAG, and DCP. Scatter plots of plasma (A) AFP, (B) AAG, and (C) DCP levels in control, AFP-low HCC,
and AFP-high HCC. The black line indicates the median, for which the value is indicated on the bottom of the scatter plot. The dashed line
indicates the cut-off value of each marker, 20 ng/mL for AFP, 800 μg/mL for AAG, and 4.5 ng/mL for DCP. In all markers, P < 0.0001 for control
vs. either AFP-low HCC or AFP-high HCC.
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nosis of HCC [19], therefore it allowed us to propose
that determining AAG levels could be helpful in early
detection of HCC or AFP-low HCC. The high level of
AAG in HCC patients with low AFP concentration
could be caused by the inflammation of the liver or the
overproduction of the acute phase protein by hepatoma
cells [12]. However, further study will be required for
clarifying the role of AAG in AFP-low HCC.
Several case-control studies showed sensitivities and
specificities of different biomarkers in the diagnosis of
HCC. A study in Japan of 1377 HCC patients and 355
non-HCC controls with chronic hepatitis or cirrhosis
showed that the utility of DCP for the diagnosis of HCC
was lower than that of AFP for small tumors, but higher
than that of AFP for large tumors [11]. Moreover, DCP
level was reported to be closely correlated with tumor
progression and prognosis, while HCC with high serum
Figure 3 ROC curves of AAG and DCP in HCC patients. ROC curves comparing AAG and DCP in (A) all HCC patients; (B) AFP-low HCC
patients; and (C) AFP-high HCC patients.
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of larger tumor size [20-22]. Similarly, we found that
DCP level increased according to the stepwise progres-
sion of liver disease, i.e., from chronic hepatitis to cir-
rhosis to HCC. The DCP level was decreased in HCC
patients with low AFP value but significantly increased
in patients with high AFP value. The sensitivity and spe-
cificity were 74% and 95%, respectively, for all HCC
patients. These values were similar to the results in
China (77% and 86.4%, respectively) [15] but higher
than the results in USA (74% and 70%, respectively).
Recent study demonstrated that AFP was more sensitive
than DCP for the diagnosis of early and very early stage
HCC at a new cutoff of 10.9 ng/mL [10]. However,
neither AFP alone, DCP alone, nor the combination of
AFP and DCP was sufficiently accurate to be used for
HCC surveillance [17]. In light of our recent results and
others, we propose to use AAG as alternative biomarker
to AFP and as a complement for ultrasound in HCC
patients with low AFP.
The most important question is whether the cut-off
value of DCP in Indonesian HCC patients was similar to
studies in other countries. We found the optimal cut-off
DCP value to be 4.5 ng/mL based on the ROC curve for
distinguishing patients with HCC from those with non-
HCC. This DCP cut-off value was lower than the value
used in studies from USA (7.5 ng/mL) [15]. This differ-
ence might be due to ethnic differences [23] as other
studies have also used varying cut-off DCP values for
Italian, Japanese and Chinese subjects [19,24]. It is also
possible that the etiology of liver disease (HBV and
HCV) can alter the DCP level. In this study, HBV was
the underlying etiology in most of our patients with
chronic hepatitis/cirrhosis and our patients with HCC.
Interestingly, we found that the non-viral etiology (non
B, non C) among HCC patients was also higher, espe-
cially for AFP-low HCC. Taken together, our results
suggest that a lower cut-off of DCP value in our study
may be related to higher HBV-infected and non B-non
C populations among Indonesian subjects. Prospective
studies on a large number of patients with diverse eth-
nic backgrounds and a broad spectrum of underlying
etiologies of liver disease are required in order to con-
firm this assumption.
Conclusion
Our cross-sectional study showed that AAG was better
performance in diagnosing HCC patients with low AFP,
while DCP did better in those with high AFP. A DCP
value of > 4.5 ng/mL and AAG value of > 800 μg/mL
among patients with underlying non-malignant liver dis-
ease were associated with a high probability of develop-
ing HCC. Prospective studies on a large number of
patients with underlying etiologies of liver disease and
tumor staging are required toc o n f i r mt h i ss t u d y .D a t a
from these studies may help to improve the outcome of
patients with HCC by enabling the diagnosis to be made
at an earlier stage of the disease when curative treat-
ment is still possible.
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